Challenges and opportunities in cancer drug development
Managing director Professor Heinz Zwierzina of the Cancer Drug Development Forum talks Health Europa through the challenges in the search for new cancer drugs.
The...
Pharmacovigilance in the EU: a closer look at EudraVigilance
Health Europa highlights the role of EudraVigilance in the pharmacovigilance activities of the EMA, from the launch of the revamped system in 2017 to...
Learning from Nature: understanding sustainable antibiotic use
There is a pressing need to better understand sustainable antibiotic use and the evolution of resistance in infectious diseases.
The evolution of antibiotic-resistant pathogens poses...
Michael Lisanti and his focus on doxycycline antibiotics
Health Europa delves further into Lisanti’s successful breast cancer clinical trial and the remarkable use of doxycycline antibiotics.
Lisanti and his wife Professor Sotgia, from...
New targeted methotrexate underway for rheumatoid arthritis
ROS Therapeutics APS has developed a targeted methotrexate prodrug to mitigate the side effects experienced by many rheumatoid arthritis patients.
Danish start-up company ROS Therapeutics...
What do you know about the Danish medical cannabis pilot programme?
Minister of Health, Ellen Trane Nørby, provides insight into the recently introduced Danish medical cannabis pilot programme and its implications.
What does the Danish medical...
CAR T-cell therapies in Europe
Health Europa reflects on the first two CAR T-cell therapies to have been recommended for approval in the European Union.
In June, the European Medicines...
Prescription cannabis in UK: have the law and the drug become best buds?
The UK government has announced that patients can receive prescription cannabis by specialist doctors from 1 November 2018.
Health Europa previously reported upon the review...
The legal medical cannabis movement
Health Europa explores the various approaches to medical cannabis, as more and more countries around the world move in favour of legalisation.
With medical cannabis...
How is Brexit expected to impact UK pharmacovigilance?
As the UK readies itself to leave the EU, the Pharmaceutical Information and Pharmacovigilance Association’s Sarah Hall considers the potential impact of Brexit on...
Ciprofloxacin side effects dramatically affect the mitochondrial genome
Antibiotics are to be used cautiously with Ciprofloxacin side effects causing severe issues on metabolism, according to a study carried out at the University...
Johnson & Johnson: collaboration advancing novel vaccine development for MERS
Johnson & Johnson announced today a new collaboration that will support novel vaccine development against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Janssen Vaccines & Prevention...
Platome Biotechnology – advancing cellular therapies
Icelandic company Platome Biotechnology is reinventing cell culture to help speed up the development of approved cellular therapies.
Regenerative medicine will play a key role...
Scandal: NHS patients given contaminated blood
Public inquiry has begun regarding how thousands of NHS patients were given blood products infected with hepatitis and HIV during the 1970s and 1980s,...
Tilray exports 2:100 CBD oil to the United Kingdom
Tilray® Inc., a global leader in cannabis research, production and distribution, announced today that Tilray 2:100, a product produced at Tilray’s federally licensed, Good Manufacturing...
UCLA discovers 8,000 surprisingly effective combinations of antibiotics
Biologists at the University of California, Los Angeles (UCLA) have uncovered thousands of four- and five-drug combinations of antibiotics that are surprisingly effective.
The discovery...
Safeguarding the availability of medicines in the EU
In its newly published work programme for 2019/20, an EU-wide task force has set out a series of necessary actions to ensure the availability...
Infection and inflammation, is there medication for the future?
A new study has mapped how the body’s own peptides act to reduce infection and inflammation by deactivating the toxic substances formed in the...
EMA responds to liver injury concerns over uterine fibroids medicine
The European Medicines Agency (EMA) has responded to concerns that Esmya (ulipristal acetate), a uterine fibroids medicine, presents a risk of serious liver injury.
Having...
Will a no-deal Brexit impact insulin supply getting into the UK?
Diabetes UK has responded to recent concerns from the chair of the Medicines and Healthcare products Regulatory Authority (MHRA), Sir Michael Rawlins, that a...
